Wednesday, March 10, 2010
Diamyd Medical: Diamyd US Phase III Study Well Under Way
Diamyd Medical (STO:DIAMB)(Pink Sheets:DMYDY) announces today that one hundred study participants have been included in the ongoing US Phase III study, DiaPrevent. The global Phase III program with the company's lead drug candidate Diamyd® has thereby enrolled more than 430 children newly diagnosed with type 1 diabetes in Europe and the USA...
Subscribe to:
Post Comments (Atom)
Search This Blog
Please Visit Our Sponsors Below
SBI Site Build It For Web Publishers
0 comments:
Post a Comment